Sara Algeelani

Sara

Sara Algeelani
DPharm, Pharmacy
Kind Saud University
Riyadh, Saudi Arabia
MS Student in Pharmacology & Drug Development
David Greenblatt, MD, Adviser

 

 

 

Hepatic metabolism increases the polarity (water solubility) of drugs so that they can be easily excreted form the body. Some drugs undergo either phase I (oxidation, reduction, and hydroxylation) or phase ll (Conjugation) metabolism. However, the majority undergo phase l followed by phase ll, thereby Phase ll metabolism detoxify the reactive metabolite of phase l metabolism. Canagliflozin, a sodium-dependent glucose transport 2 (SGLT2) inhibitor, is an innovative drug approved to treat adults with type 2 diabetes mellitus. Phase ll glucuronidation reaction is the major metabolic elimination pathway for canagliflozin. I am testing the possible inhibitory effect of other anti-diabetic drugs on the metabolism of canagliflozin. Using an in vitro system with human liver microsomes (HLMs), I'm studying the inhibition profile of uridine 5'-diphospho-glucuronosyltransferases (UGTs) isoenzymes which are the major metabolizing enzymes that catalyze phase II biotransformation reactions.

Back to the Greenblatt Profile Page

Apply to the Sackler School

apply

The priority application deadlines are as follows:

December 1: Basic Science Division PhD Programs

February 15: Building Diversity in Biomedical Sciences

March 31: Post-Baccalaureate Research Program

May 1: Clinical & Translational Science, MS in Pharmacology & Drug Development

June 15: Online Certificate in Fundamentals of Clinical Care Research